AURA vs VSTM
AURA: Aura Biosciences is a clinical-stage biotech developing precision Viral-like Drug Conjugate (VDC) therapies designed to treat solid tumors while preserving organ function. VSTM: A biopharmaceutical company developing targeted therapies for RAS/MAPK pathway-driven cancers, with a newly FDA-approved combination treatment for KRAS-mutated ovarian cancer and a pipeline focused on direct KRAS G12D inhibition.
Side-by-side fundamentals
| Metric | AURA | VSTM | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $7.16 | $6.08 | |
| Market cap as of 2026-07-31 | $740M | $534M | |
| Net margin as of 2026-07-31 | n/a | -391.2% | |
| Gross margin as of 2026-07-31 | n/a | +85.1% | |
| Operating margin as of 2026-07-31 | n/a | -344.6% | |
| ROE as of 2026-07-31 | -78.1% | -163.6% | AURA higher |
| ROA as of 2026-07-31 | -64.1% | -91.6% | AURA higher |
| Debt / equity as of 2026-07-31 | 0.00 | 1.01 | AURA lower |
| Revenue growth (YoY) as of 2026-07-31 | n/a | +209.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +97.0% | |
| Beta as of 2026-07-31 | 0.40 | 0.26 | |
| 1-year return as of 2026-07-27 close | -1.0% | -1.0% | AURA higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.